Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
EMA grants Orphan Drug Designation to investigational QRX003 for Peeling Skin Syndrome, its eighth regulatory designation across two indications.